I was at a private investor summit last November when a biotech analyst stood up to announce that 2025 had been the worst year for rare-disease pipelines since the 2008 financial crisis. They pointed to a litany of delayed filings, blown budgets, and FDA non-decision letters. Then, quietly, someone slid a printout across the table […]